Sign In
Buy MRK
$120.78
+1.69 (+1.41%)
At Close: Jun 11, 2026
Merck's endometrial cancer drug meets late-stage trial goals
06:51am, Monday, 18'th May 2026
Merck said on Monday its experimental endometrial cancer drug met the main goals of a late-stage trial.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's TroFuse-005 Trial Evaluating Sac-TMT Met Primary Endpoints of OS and PFS in Certain Patients With Advanced or Recurrent Endometrial Cancer.
Why Is Regeneron Stock Sinking Monday?
06:28am, Monday, 18'th May 2026
Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free survival in the high-dose arm.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
10:01am, Thursday, 14'th May 2026
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally
01:15pm, Wednesday, 13'th May 2026
The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.
Will Keytruda Continue to Aid MRK's Growth in 2026 After a Strong Q1?
12:52pm, Wednesday, 13'th May 2026
Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could fuel the drug's overall growth through 2026.
Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026
06:45am, Tuesday, 12'th May 2026
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 abstracts across over 25 types of
The Zacks Analyst Blog UnitedHealth, Merck & Co., Qualcomm, EVI and Optex
05:36am, Tuesday, 12'th May 2026
UNH, MRK and QCOM drew focus as analysts highlighted growth drivers, pipeline strength and expanding AI and automotive opportunities.
Merck Stock Down 7% in a Month: Should Investors Hold or Exit?
12:21pm, Monday, 11'th May 2026
Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners. However, Keytruda and new launches support growth.
2 Dividend Stocks to Double Up On Right Now
01:30pm, Friday, 08'th May 2026
Amgen is handling a recent patent cliff pretty well. Merck is well prepared for its own upcoming patent cliff.
Merck Faces Gardasil Trial After $8.9 Billion Sales Peak
01:22pm, Friday, 08'th May 2026
Merck (MRK) is moving toward a potentially high-stakes courtroom test over Gardasil, its HPV vaccine, as personal injury lawyers try to convince a Los Angeles j
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the publication of work describing the large-scale synthesis of enlicitide decanoat
6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash
10:32am, Wednesday, 06'th May 2026
Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck.
SAN FRANCISCO & RAHWAY, N.J.--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world's #1 AI CRM, and Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of
Pre-Market Stock Futures: Futures are trading higher on Wednesday as news of an impending end to the Iran war is sending oil prices dramatically lower. This news comes after a bounce-back Tuesday that
